Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct;18(10):45.
doi: 10.1007/s11940-016-0427-0.

Treatment Options for Urogenital Dysfunction in Parkinson's Disease

Amit Batla  1 , Natalie Tayim  2 , Mahreen Pakzad  2 , Jalesh N Panicker  3
Affiliations
Review

Treatment Options for Urogenital Dysfunction in Parkinson's Disease

Amit Batla et al. Curr Treat Options Neurol. 2016 Oct.

Abstract

Urogenital dysfunction is commonly reported in Parkinson's disease (PD), and history taking and a bladder diary form the cornerstone of evaluation. The assessment of lower urinary tract (LUT) symptoms include urinalysis, ultrasonography, and urodynamic studies and help to evaluate concomitant urological pathologies such as benign prostate enlargement. Antimuscarinic medications are the first line treatment for overactive bladder (OAB) symptoms and solifenacin has been specifically studied in PD. Antimuscarininc drugs may exacerbate PD-related constipation and xerostomia, and caution is advised when using these medications in individuals where cognitive impairment is suspected. Desmopressin is effective for the management of nocturnal polyuria which has been reported to be common in PD. Intradetrusor injections of botulinum toxin have been shown to be effective for detrusor overactivity, however, are associated with the risk of urinary retention. Neuromodulation is a promising, minimally invasive treatment for PD-related OAB symptoms. Erectile dysfunction is commonly reported and first line treatments include phosphodiesterase-5 inhibitors. A patient-tailored approach is required for the optimal management of urogenital dysfunction in PD.

Keywords: Bladder diary Parkinson’s disease; Detrusor overactivity; Erectile dysfunction; Incontinence; Lower urinary tract; Urodynamics.

PubMed Disclaimer

Conflict of interest statement

Amit Batla and Natalie Tayim each declare no potential conflicts of interest. Mahreen Pakzad has been a speaker for Astellas. Jalesh N. Panicker has received royalties from Cambridge University Press, has been involved in trials supported by FirstKind Ltd, Allergan and Ipsen and has received speaker honoraria from Wellspect, Astellas and Allergan. Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical E Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–45. doi: 10.1016/S1474-4422(06)70373-8. - DOI - PubMed
    1. Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, et al. The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study) Move dis: off J Move Dis Soc. 2015;30(2):229–37. doi: 10.1002/mds.26077. - DOI - PubMed
    1. Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T. Pathophysiology of bladder dysfunction in Parkinson’s disease. Neurobiol Dis. 2011. - PubMed
    1. Andersen JT. Disturbances of bladder and urethral function in Parkinson’s disease. Int Urol Nephrol. 1985;17(1):35–41. doi: 10.1007/BF02089401. - DOI - PubMed
    1. Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T. Pathophysiology of bladder dysfunction in Parkinson’s disease. Neurobiol Dis. 2012;46(3):565–71. doi: 10.1016/j.nbd.2011.10.002. - DOI - PubMed

LinkOut - more resources